Efficacy Results of a Trial of a Herpes Simplex Vaccine

Belshe, Robert B.; Leone, Peter A.; Bernstein, David I.; Wald, Anna; Levin, Myron J.; Stapleton, Jack T.; Gorfinkel, Iris; Morrow, Rhoda L. Ashley; Ewell, Marian G.; Stokes-Riner, Abbie; Dubin, Gary; Heineman, Thomas C.; Schulte, Joann M.; Deal, Carolyn D.
January 2012
New England Journal of Medicine;1/5/2012, Vol. 366 Issue 1, p34
Academic Journal
Background: Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negative for both HSV type 1 (HSV-1) and HSV-2 antibodies. Efficacy was not observed in men or HSV-1 seropositive women. Methods: We conducted a randomized, double-blind efficacy field trial involving 8323 women 18 to 30 years of age who were negative for antibodies to HSV-1 and HSV-2. At months 0, 1, and 6, some subjects received the investigational vaccine, consisting of 20 �g of glycoprotein D from HSV-2 with alum and 3-O-deacylated monophosphoryl lipid A as an adjuvant; control subjects received the hepatitis A vaccine, at a dose of 720 enzyme-linked immunosorbent assay (ELISA) units. The primary end point was occurrence of genital herpes disease due to either HSV-1 or HSV-2 from month 2 (1 month after dose 2) through month 20. Results: The HSV vaccine was associated with an increased risk of local reactions as compared with the control vaccine, and it elicited ELISA and neutralizing antibodies to HSV-2. Overall, the vaccine was not efficacious; vaccine efficacy was 20% (95% confidence interval [CI], -29 to 50) against genital herpes disease. However, efficacy against HSV-1 genital disease was 58% (95% CI, 12 to 80). Vaccine efficacy against HSV-1 infection (with or without disease) was 35% (95% CI, 13 to 52), but efficacy against HSV-2 infection was not observed (-8%; 95% CI, -59 to 26). Conclusions: In a study population that was representative of the general population of HSV-1� and HSV-2�seronegative women, the investigational vaccine was effective in preventing HSV-1 genital disease and infection but not in preventing HSV-2 disease or infection. (Funded by the National Institute of Allergy and Infectious Diseases and GlaxoSmithKline; ClinicalTrials.gov number, NCT00057330.)


Related Articles

  • Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. Morrow, Rhoda Ashley; Friedrich, David; Meier, Amalia; Corey, Lawrence // BMC Infectious Diseases;2005, Vol. 5 Issue 1, p1 

    Background: Commercially available assays to detect antibodies to the herpes simplex virus type 2 (HSV-2)-specific glycoprotein gG-2 have markedly improved serologic diagnosis of HSV-2 infection. However, even tests with high specificity can have low positive predictive values in low prevalence...

  • Inability of Enzyme Immunoassays to Discriminate between Infections with Herpes Simplex Virus Types 1 and 2. Ashley, Rhoda; Cent, Anne; Maggs, Vanna; Nahmias, Andre; Corey, Lawrence // Annals of Internal Medicine;10/1/91, Vol. 115 Issue 7, p520 

    Presents information on a study which determined the accuracy of several commercial enzyme immunoassays in detecting and subtyping antibodies to herpes simplex virus. Incidence of genital herpes simplex virus infections; Methodology; Results of the study.

  • Currently Licensed Immunoassays Do Not Accurately Distinguish Antibodies to Herpes Simplex Virus Subtypes. Healy, Bernadine // JAMA: Journal of the American Medical Association;12/4/91, Vol. 266 Issue 21, p2955 

    Discusses the detection of antibodies from herpes simplex virus detected patients by commercially licensed enzyme immunoassays. Use of Western blot and glycoprotein G immunodot enzyme assays; Verification of the accuracy of the immunoassays; Identification of seronegative patients.

  • What's the best test for HSV-2 after exposure? Heintzman, John; Rugge, Bruin; Judkins, Dolores Zegar // Journal of Family Practice;Mar2007, Vol. 56 Issue 3, p221 

    The article discusses the cross-sectional study which states that enzyme-linked immunosorbent assay (ELISA) tests have shown high sensitivity and specificity in determining seropositivity for herpes simplex virus II (HSV-2) antibodies in the U.S. However, they are less specific for HSV-2 and are...

  • Serological Profile of HSV-2 in STD Patients: Evaluation of Diagnostic Utility of HSV-2 IgM and IgG Detection. AMUDHA, V. P.; RASHETHA; SUCILATHANGAM, G.; CINTHUJAH, B.; REVATHY, C. // Journal of Clinical & Diagnostic Research;Dec2014, Vol. 8 Issue 12, p16 

    Background and Objectives: The present study was undertaken to determine Herpes Simplex Virus-2 seroprevalence in sexually active adults aged 20-49 and to investigate the correlation with sociodemographic characteristics and to find its association with other sexually transmitted diseases...

  • Prevalence of HSV-2 antibodies among STD clinic patients in Tanzania. Langeland, N.; Haarr, L.; Mhalu, F. // International Journal of STD & AIDS;Feb1998, Vol. 9 Issue 2, p104 

    Patients attending a referral sexually transmissible diseases clinic at Muhimbili Medical Centre in Dar-es-Salaam during the period 1989 to 1993 were examined for herpes simplex virus type 2 (HSV-2) antibodies. An ELISA technique, using glycoprotein G of HSV-2 as antigen, was used to test 294...

  • State of the Globe: Detecting HSV in Clinical Setting. Vanjeri, Sheetal; Galwankar, Sagar // Journal of Global Infectious Diseases;Jul2012, Vol. 4 Issue 3, p139 

    The authors reflect on the study towards the detection of herpes simplex virus (HSV) infection. They mention the analysis of the demographic distribution of sexually transmitted diseases (STD). They also note that 150 patients with the said disease were tested for specific antibodies through...

  • A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica. Rodríguez, A. C.; Castle, P. E.; Smith, J. S.; Bratti, C.; Hildesheim, A.; Schiffman, M.; Viscidi, R.; Burk, R. D.; Ashley, R. L.; Castellsagué, X.; Herrero, R.; Rodríguez, A C; Castellsagué, X // Sexually Transmitted Infections;Dec2003, Vol. 79 Issue 6, p460 

    Objectives: To determine seroprevalence and determinants of herpes simplex virus 2 (HSV-2) seropositivity, in a random sample of a population based cohort of 10 049 women of Guanacaste, Costa Rica, using a highly sensitive and specific serological assay.Methods:...

  • Antibody Testing for Herpes Simplex Virus (HSV) Type 2 (HSV-2).  // Clinical Infectious Diseases;4/1/2006, Vol. 42 Issue 7, preceding p1 

    The article examines the common use of inaccurate antibody assays to identify infection status with herpes simplex virus type 2 (HSV-2). The participating laboratories in the study tested positive for HSV type 1 (HSV-1) antibodies but negative for HSV-2 antibodies on the serum samples. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics